

IC ₅₀ in μ M	Solid Tumor Cell Line				Leukemia			
	Hela	MDA-MB468	MDA-MB231	PC-3	K562	*KG-1	MV4-11	RS4;11
1	0.6731	0.3500	0.3000	0.545	0.4296	0.5206	1.504	1.287
82	0.1620	0.1200	0.0960	0.165	0.0520	0.1092	0.560	0.218
95	0.0486	0.0370	0.0320	0.0600	0.0349	0.0289	0.231	0.254
99	0.0427	0.0400	0.0200	0.0580	0.0163	0.0187	0.188	0.096

Figure 1A

IC ₅₀ in μ M	Normal Cell			
	WI-38 ^{#2}	RPTEC	*HuVec	*HAoSMC
1	>10	>10	>9	>9
82	>10	>10	>9	>9
95	>10	>10	>9	>9
99	>10	>10	>9	>9

Figure 1B




Figure 2A




Figure 2B




Figure 2C




Figure 2D

Drug treatment	0hr	24hr	48hr
1	12.3%	42.2%	77.8%
42	12.3%	49.5%	79.6%
82	19%	56%	69%
95	19%	43%	77%

Figure 3

IC ₅₀ (μ M) or % inhibition			
Kinase	Compounds	"82"	"95"
CHK1		> 10	> 10
CHK2		> 10	> 10
Cdk1/cyclin B		> 10	> 10
Aurora A		> 10	> 10
Aurora B		> 10	> 10
mTOR		> 10	> 10
PI3K α		> 10	> 10
PI3K β		> 10	> 10
VEGFR-2		> 10	> 10
PDGFR- β		> 10	> 10
FGFR-1		> 10	> 10
EGFR		> 10	> 10
EGFR(T790M)		> 10	> 10
IGF1-R		> 10	> 10
B-Raf		> 10	> 10
B-Raf(V600E)		> 10	> 10
C-Raf		> 10	> 10
Flt3		> 10	> 1
c-Met		> 10	> 10
Kit		> 10	> 10

Figure 4




Figure 5A




Figure 5B